PL2231667T3 - Inhibitory beta-laktamazy - Google Patents

Inhibitory beta-laktamazy

Info

Publication number
PL2231667T3
PL2231667T3 PL09701487T PL09701487T PL2231667T3 PL 2231667 T3 PL2231667 T3 PL 2231667T3 PL 09701487 T PL09701487 T PL 09701487T PL 09701487 T PL09701487 T PL 09701487T PL 2231667 T3 PL2231667 T3 PL 2231667T3
Authority
PL
Poland
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Application number
PL09701487T
Other languages
English (en)
Inventor
Timothy A Blizzard
Helen Chen
Candido Gude
Jeffrey D Hermes
Jason E Imbriglio
Seongkon Kim
Jane Y Wu
Sookhee Ha
Christopher J Mortko
Ian Mangion
Nelo Rivera
Rebecca T Ruck
Michael Shevlin
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2231667T3 publication Critical patent/PL2231667T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pyrrole Compounds (AREA)
PL09701487T 2008-01-18 2009-01-15 Inhibitory beta-laktamazy PL2231667T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
EP09701487.2A EP2231667B1 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors
PCT/US2009/031047 WO2009091856A2 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
PL2231667T3 true PL2231667T3 (pl) 2014-01-31

Family

ID=40642204

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13180969T PL2666774T3 (pl) 2008-01-18 2009-01-15 Inhibitory beta-laktamazy
PL09701487T PL2231667T3 (pl) 2008-01-18 2009-01-15 Inhibitory beta-laktamazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13180969T PL2666774T3 (pl) 2008-01-18 2009-01-15 Inhibitory beta-laktamazy

Country Status (38)

Country Link
US (2) US8487093B2 (pl)
EP (2) EP2666774B1 (pl)
JP (3) JP5038509B2 (pl)
KR (2) KR101648728B1 (pl)
CN (2) CN101918407B (pl)
AU (1) AU2009206119C1 (pl)
BR (1) BRPI0906871B1 (pl)
CA (1) CA2712783C (pl)
CO (1) CO6331438A2 (pl)
CR (1) CR11626A (pl)
CY (5) CY1114900T1 (pl)
DK (2) DK2666774T3 (pl)
DO (1) DOP2010000218A (pl)
EC (2) ECSP10010345A (pl)
ES (2) ES2433744T3 (pl)
FR (3) FR20C1031I2 (pl)
HN (1) HN2010001395A (pl)
HR (2) HRP20131123T1 (pl)
HU (2) HUS000513I2 (pl)
IL (1) IL206395A (pl)
LT (3) LTC2231667I2 (pl)
LU (1) LUC00165I2 (pl)
MA (1) MA32025B1 (pl)
ME (1) ME02089B (pl)
MX (1) MX2010007823A (pl)
MY (1) MY162532A (pl)
NI (1) NI201000115A (pl)
NL (3) NL301051I2 (pl)
NO (3) NO2020022I1 (pl)
NZ (1) NZ586861A (pl)
PL (2) PL2666774T3 (pl)
PT (2) PT2231667E (pl)
RS (2) RS53052B (pl)
RU (1) RU2445314C9 (pl)
SI (2) SI2231667T1 (pl)
UA (1) UA101966C2 (pl)
WO (1) WO2009091856A2 (pl)
ZA (1) ZA201005333B (pl)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009206119C1 (en) * 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SG10201510576WA (en) * 2010-12-22 2016-01-28 Meiji Seika Pharma Co Ltd Optically active diazabicyclooctane derivative and process for preparing the same
KR102143660B1 (ko) * 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
PL2748165T3 (pl) 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
ES2606059T3 (es) * 2011-08-30 2017-03-17 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
JP2015506360A (ja) 2012-01-06 2015-03-02 ユニバーシティ・オブ・サウス・フロリダ 組成物、使用方法および処置方法
SG11201406120SA (en) * 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) * 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013237939A1 (en) * 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2847327B1 (en) 2012-05-08 2018-12-26 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3360877B1 (en) 2012-08-25 2021-02-17 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2014069351A1 (ja) 2012-11-01 2014-05-08 株式会社カネカ 光学活性二環式ウレア化合物の製造方法
CN105026407B (zh) * 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX382981B (es) 2013-03-08 2025-03-12 Wockhardt Ltd Proceso para la preparacion de (2s, 5r)-7-oxo-6-sulfooxi-2-[((3r)-piperidin-3-carbonil)carbonil hidrazino]-1,6-diaza-biciclo[3.2.1] -octano.
CA2904082C (en) * 2013-03-08 2017-10-03 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
NZ711329A (en) 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)- sulfuric acid mono-{ [(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
JP6253676B2 (ja) * 2013-03-08 2017-12-27 ウォックハート リミテッド （２ｓ，５ｒ）−２−カルボキシアミド−７−オキソ−６−スルホオキシ−１，６−ジアザ−ビシクロ［３．２．１］オクタンのナトリウム塩のためのプロセス
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014152996A1 (en) * 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
EP3008069B1 (en) * 2013-06-10 2018-01-03 Merck Sharp & Dohme Corp. Preparation of tert-butyl 4-((1r,2s,5r)-6- (benzyloxy)-7-0x0-1,6-diazabicycl0[3.2.i]octane-2- carboxamido)piperidine-1-carboxylate
CN105555787B (zh) 2013-09-24 2017-08-08 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法及其中间体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CA2926071C (en) 2013-10-08 2021-11-09 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015079329A2 (en) * 2013-11-26 2015-06-04 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
IN2014MU01196A (pl) * 2014-03-29 2015-10-02 Wockhardt Ltd
WO2015150891A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
PL3604316T3 (pl) 2014-05-05 2024-04-29 Melinta Therapeutics, Inc. Synteza soli boronianowych
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
MY196240A (en) 2014-11-17 2023-03-24 Entasis Therapeutics Ltd Combination Therapy for Treatment Of Resistant Bacterial Infections
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016089718A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
AU2015355970B2 (en) 2014-12-05 2020-05-21 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TW201639853A (zh) * 2015-03-31 2016-11-16 木塔比利斯公司 雜環化合物及其於預防或治療細菌感染之用途
BR112017023359A2 (pt) * 2015-05-07 2018-07-17 Mutabilis ?compostos, composições farmacêuticas e kits?
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP3281942A4 (en) * 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
JP2018530553A (ja) 2015-10-02 2018-10-18 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． β−ラクタマーゼを阻害するための組成物及び方法
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3386982A1 (en) * 2015-12-11 2018-10-17 The Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
WO2017136254A1 (en) 2016-02-04 2017-08-10 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
WO2017167218A1 (zh) * 2016-03-31 2017-10-05 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
IL263448B2 (en) 2016-06-09 2023-10-01 Codexis Inc Biological catalysts and methods for hydroxylation of chemical compounds
JP7060245B2 (ja) 2016-06-30 2022-04-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
EP3512851B1 (en) 2016-09-16 2022-07-06 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
EP3515915B1 (en) * 2016-09-19 2021-08-04 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
MY201377A (en) 2017-05-08 2024-02-21 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN110446708B (zh) 2017-07-21 2022-12-02 安塔比奥公司 化学化合物
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN111417633B (zh) 2017-12-01 2022-05-06 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的晶型及其制备方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
AU2019211693B2 (en) * 2018-01-25 2023-12-21 Evopoint Biosciences Co., Ltd. Beta-lactamase inhibitor and use thereof
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
FI3833665T3 (fi) * 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
JP7523354B2 (ja) * 2018-09-21 2024-07-26 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
WO2020072442A1 (en) * 2018-10-01 2020-04-09 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
AU2019386849B2 (en) 2018-11-29 2025-07-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
CA3133071A1 (en) 2019-03-12 2020-09-17 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
EP3959205B1 (en) * 2019-04-26 2025-11-12 Merck Sharp & Dohme LLC Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
JP7647110B2 (ja) * 2020-01-22 2025-03-18 日油株式会社 ポリエーテルエステル化合物
CN115151544B (zh) 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
US20250302846A1 (en) * 2022-05-11 2025-10-02 The Regents Of The University Of Colorado A Body Corporate Antibiotic composition and methods of use thereof
CN117384169B (zh) * 2022-07-05 2025-10-17 福安药业集团重庆三禾兴医药科技有限公司 一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
DK0508234T3 (da) 1991-04-11 1996-10-28 Hoffmann La Roche Beta-lactamer
AU699465B2 (en) 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
JP3199300B2 (ja) * 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
CZ298246B6 (cs) 1995-12-21 2007-08-01 Sankyo Company Limited Deriváty 1-methylkarbapenu, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) * 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
KR100686988B1 (ko) 1999-07-06 2007-02-27 메틸진, 인크. β-락타마제의 술폰아미도메틸 포스포네이트 저해제
JP2003506438A (ja) * 1999-08-10 2003-02-18 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 抗菌剤
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
SK5982003A3 (en) 2000-11-16 2004-05-04 Sankyo Co 1-Methylcarbapenem derivatives
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) * 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
EP2319828A3 (en) 2003-07-09 2011-07-06 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
CA2540646A1 (en) * 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibacterial amide macrocycles
WO2005082050A2 (en) 2004-02-24 2005-09-09 Ssci, Inc. Analysis and screening of solid forms using the atomic pair distribution function
DK1965798T3 (da) 2005-12-07 2011-11-28 Basilea Pharmaceutica Ag Nyttige monobactam-antibiotika
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
AU2009206119C1 (en) * 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors

Also Published As

Publication number Publication date
HRP20131123T1 (hr) 2013-12-20
LTPA2020516I1 (lt) 2020-07-27
LTPA2020518I1 (lt) 2020-07-27
NO2020022I1 (no) 2020-08-10
JP5422020B2 (ja) 2014-02-19
CO6331438A2 (es) 2011-10-20
CN102827067B (zh) 2015-09-23
CY2020025I2 (el) 2020-11-25
ECSP10010568A (es) 2010-11-30
EP2231667A2 (en) 2010-09-29
KR101800610B1 (ko) 2017-11-23
HK1186180A1 (en) 2014-03-07
KR20160099117A (ko) 2016-08-19
HUS2000024I1 (hu) 2021-03-29
CN102827067A (zh) 2012-12-19
CY2020025I1 (el) 2020-11-25
HUS000504I2 (hu) 2021-03-29
JP2011207900A (ja) 2011-10-20
MX2010007823A (es) 2010-08-10
DOP2010000218A (es) 2010-08-31
ES2533826T3 (es) 2015-04-15
EP2666774A1 (en) 2013-11-27
AU2009206119B2 (en) 2012-06-07
MY162532A (en) 2017-06-15
CR11626A (es) 2010-09-13
CY1114900T1 (el) 2016-12-14
CY1116243T1 (el) 2017-03-15
NZ586861A (en) 2011-12-22
IL206395A0 (en) 2010-12-30
US20110294777A1 (en) 2011-12-01
HUS2000023I1 (hu) 2021-03-29
ZA201005333B (en) 2011-04-28
MA32025B1 (fr) 2011-01-03
JP2011510012A (ja) 2011-03-31
DK2231667T3 (da) 2013-12-16
ME02089B (me) 2014-04-30
JP5597164B2 (ja) 2014-10-01
FR20C1030I2 (fr) 2021-08-27
PT2666774E (pt) 2015-04-13
IL206395A (en) 2015-04-30
LUC00165I2 (pl) 2021-08-16
SI2231667T1 (sl) 2013-12-31
NL301052I2 (nl) 2026-02-03
PL2666774T3 (pl) 2015-06-30
KR101648728B1 (ko) 2016-08-17
RS53052B (sr) 2014-04-30
CY2020024I2 (el) 2020-11-25
RU2445314C9 (ru) 2013-04-10
HK1143809A1 (en) 2011-01-14
RU2445314C1 (ru) 2012-03-20
FR20C1031I1 (pl) 2020-02-10
SI2666774T1 (sl) 2015-04-30
WO2009091856A3 (en) 2009-12-03
LTPA2020517I1 (lt) 2020-07-27
CA2712783A1 (en) 2009-07-23
CN101918407A (zh) 2010-12-15
CY2020024I1 (el) 2020-11-25
CN101918407B (zh) 2014-02-26
JP5038509B2 (ja) 2012-10-03
FR20C1032I1 (pl) 2020-02-10
LTC2666774I2 (lt) 2022-01-25
LTC2231667I2 (lt) 2021-07-26
NO2020023I1 (no) 2020-08-10
BRPI0906871A2 (pt) 2020-07-28
CY2020023I1 (el) 2020-11-25
HUS000513I2 (hu) 2021-03-29
KR20100130176A (ko) 2010-12-10
UA101966C2 (xx) 2013-05-27
WO2009091856A2 (en) 2009-07-23
AU2009206119A1 (en) 2009-07-23
RS53862B1 (sr) 2015-08-31
DK2666774T3 (en) 2015-03-23
CA2712783C (en) 2013-03-19
HN2010001395A (es) 2012-11-12
FR20C1031I2 (fr) 2022-07-29
US8487093B2 (en) 2013-07-16
EP2231667B1 (en) 2013-09-04
BRPI0906871B1 (pt) 2021-09-28
ES2433744T3 (es) 2013-12-12
AU2009206119C1 (en) 2016-05-26
NI201000115A (es) 2011-07-08
NL301050I2 (nl) 2020-09-03
FR20C1032I2 (fr) 2022-07-29
NO2020024I1 (no) 2020-08-10
CY2020023I2 (el) 2020-11-25
NL301051I2 (nl) 2020-09-03
JP2012214475A (ja) 2012-11-08
HRP20150269T1 (hr) 2015-04-24
EP2666774B1 (en) 2015-01-07
PT2231667E (pt) 2013-12-13
US20130274475A1 (en) 2013-10-17
ECSP10010345A (es) 2010-08-31
FR20C1030I1 (fr) 2020-02-10

Similar Documents

Publication Publication Date Title
CY2020025I1 (el) Αναστολεις βητα-λακταμασων
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
EP2305306A4 (en) NEURO INVASION INHIBITOR
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0810374A2 (pt) Inibidores específicos do pdgfrbeta
BRPI0918564A2 (pt) inibidores
IL205205A0 (en) Beta - lactamase inhibitors
BRPI0814797A2 (pt) Inibidores dna-pk
DK2066662T3 (da) Serinhydrolaseinhibitorer
EP2177529A4 (en) NEW SECRETASE HEMMER
DK2331548T3 (da) Proteasehæmmere
BRPI0912564A2 (pt) inibidores de jnk
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt) inibidores de protease
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
TH148533B (th) ตัวยับยั้ง c-fms ไคเนส
TH0801005303A (th) สารยับยั้ง c-fms ไคเนส
TH0801000834A (th) ตัวยับยั้งเฮเทอโรไซคลิก แอสพาร์ทิลโปรตีเอส